Welcome to our dedicated page for Enliven Therapeutics SEC filings (Ticker: ELVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enliven Therapeutics SEC filings document a clinical-stage biopharmaceutical issuer developing small-molecule therapeutics, with disclosures centered on ELVN-001 for chronic myeloid leukemia and related operating results and cash resources. Current reports furnish quarterly and annual financial results and attach business updates describing ENABLE clinical-trial activity, regulatory-development topics, and program plans.
Proxy and governance filings describe annual meeting matters, board composition, committee leadership, executive transitions, director compensation, equity awards, and stockholder voting procedures. The filings also identify Enliven common stock on the Nasdaq Global Select Market and record material-event amendments when furnished press-release exhibits are corrected.
Enliven Therapeutics reported a net loss of $23.6M, or $0.38 per share, for the three months ended March 31, 2026, compared with a $28.5M loss a year earlier. Research and development spending declined to $20.7M, while general and administrative expenses were $7.1M. The company ended the quarter with $452.4M in cash, cash equivalents and marketable securities, which management believes will fund operations for at least 12 months. Enliven is prioritizing its BCR-ABL program, advancing ELVN-001 toward a pivotal trial, and is exploring strategic alternatives for ELVN-002 and has decided not to develop its HER2 program beyond 2025.
Enliven Therapeutics reported first quarter 2026 results, highlighting progress on its chronic myeloid leukemia candidate ELVN-001 and a strong cash position. ELVN-001 showed positive initial Phase 1b data, with additional Phase 1 results expected mid-2026 and initiation of the Phase 3 ENABLE-2 pivotal trial planned for the second half of 2026.
For the quarter ended March 31, 2026, Enliven posted a net loss of $23.6 million, improving from $28.5 million a year earlier. Research and development expenses were $20.7 million versus $24.9 million, while general and administrative costs were $7.1 million versus $6.8 million. Cash, cash equivalents and marketable securities totaled $452.4 million, expected to fund operations into the first half of 2029.
Enliven Therapeutics director Joseph Lyssikatos reported proposed sales of common stock under a Form 144 notice. The filing lists 25,000 shares associated with Jefferies as the broker and multiple past dispositions totaling 130,000 shares across February–March 2026 with aggregate proceeds shown per trade. The filing documents routine resale activity by an insider; timing and additional proceeds treatment are shown by the listed trade dates.
Enliven Therapeutics, Inc. is asking stockholders to vote on five proposals at its 2026 virtual annual meeting on June 9, 2026. Items include electing two Class III directors, ratifying Deloitte as auditor, and an advisory “Say‑on‑Pay” vote plus its future frequency.
A key proposal seeks to amend the Restated Certificate to increase authorized common stock from 100,000,000 to 200,000,000 shares, mainly to ensure sufficient capacity for future issuances. As of April 10, 2026, there were 60,895,009 common shares outstanding and entitled to vote.
Enliven Therapeutics chief medical officer Helen Louise Collins exercised stock options and sold shares in a pre-planned set of trades. On April 17, 2026, she exercised options to acquire 5,000 shares of common stock at $2.48 per share, then sold 5,000 shares in open-market transactions at weighted average prices around $45.81–$48.06, all under a Rule 10b5-1 trading plan adopted on October 19, 2025. After these transactions, she directly held 25,000 shares of Enliven common stock.
Enliven Therapeutics is soliciting proxies for its 2026 virtual Annual Meeting to be held June 9, 2026. Key items: election of two Class III directors, ratification of Deloitte as auditor, a proposal to increase authorized common stock, and advisory votes on executive pay and frequency. The Record Date is April 10, 2026 and 60,895,009 shares were outstanding as of that date.
Enliven Therapeutics submitted a Form 144 disclosing a proposed sale of 25,000 shares of Common Stock through Jefferies LLC, with an aggregate value listed as $914,750 and an entry date of 03/31/2026 on Nasdaq.
The filing also lists recent sales by Joseph Lyssikatos: 41,302 shares on 01/08/2026 for $993,437.48 and 91,198 shares on 01/09/2026 for $2,482,579.19, plus several other dispositions in January–February 2026.
Andrew Phillips files a Form 144 proposing sale of 26,035 shares of Common Stock. The filing shows 26,035 shares to be sold via a Stock Option Exercise on 03/31/2026 with cash proceeds to the issuer. The notice also lists prior sales of 21,844 and 1,520 shares on 02/02/2026 and 01/22/2026, respectively.
Enliven Therapeutics’ chief medical officer Helen Louise Collins exercised stock options and sold shares in a planned transaction. She exercised options for 40,000 shares of common stock at an exercise price of $2.48 per share and sold 40,000 shares at a weighted average price of $35.1006 per share. The filing states these trades were made under a Rule 10b5-1 trading plan adopted on October 19, 2025, indicating they were pre-scheduled. Following the transactions, Collins directly owns 25,000 shares of common stock and continues to hold 136,268 equity awards, including fully vested options and RSUs.